Drugs Made In America Acquisition II (NASDAQ:DMII) Issues Quarterly Earnings Results

Drugs Made In America Acquisition II (NASDAQ:DMII) issued its quarterly earnings data on Friday. The company reported $0.07 earnings per share for the quarter, FiscalAI reports.

Drugs Made In America Acquisition II Stock Down 0.0%

Shares of NASDAQ DMII opened at $10.12 on Friday. The stock has a fifty day moving average price of $10.10 and a 200 day moving average price of $10.03. Drugs Made In America Acquisition II has a 1-year low of $9.86 and a 1-year high of $10.20.

Hedge Funds Weigh In On Drugs Made In America Acquisition II

Institutional investors have recently bought and sold shares of the company. Magnetar Financial LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth $26,730,000. Glazer Capital LLC purchased a new position in Drugs Made In America Acquisition II during the fourth quarter worth about $23,264,000. First Trust Capital Management L.P. purchased a new stake in Drugs Made In America Acquisition II in the 4th quarter valued at approximately $20,474,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Drugs Made In America Acquisition II during the 1st quarter worth approximately $19,960,000. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Drugs Made In America Acquisition II during the 4th quarter worth approximately $19,493,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Drugs Made In America Acquisition II presently has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.